Clinical trials: Pseudomonas Infection
Cystic Fibrosis, Bacterial Infections
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency of acute pulmonary exacerbation in patients with…
- Trial name
- NCT00004747
- Testing
- mucoid exopolysaccharide P. aeruginosa immune globulin IV
- Volunteers
- 170 people
- Sponsor
- National Center for Research Resources (NCRR)
Surgical Wound Infection, Cross Infection
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease…
- Trial name
- ESKAPE (NCT04900298)
- Testing
- SafeHaven Automated Hand Hygiene Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Joint Infection
Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa
This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip.
- Trial name
- NCT06798168
- Testing
- Combining bacteriophage therapy with antibiotics for a case with hip PJI
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Breast Cancer
Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)
The progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy capecitabine.
- Trial name
- NCT01380808
- Testing
- capecitabine and pseudomonas aeruginosa combination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Cystic Fibrosis
Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF
The purpose of this study is to determine if inhaled urea can be used to detect the presence of Pseudomonas Aeruginosa in the lungs
- Trial name
- NCT01303068
- Testing
- 13C urea breath test Kit
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Cystic Fibrosis
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa.
- Trial name
- NCT01316276
- Testing
- Liposomal amikacin for inhalation
- Where
- 50 sites in Austria, Belgium and 15 more
- Volunteers
- 206 people
- Sponsor
- Insmed Incorporated
Wound Infection
Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients.
- Trial name
- PHAGOBURN (NCT02116010)
- Testing
- E. coli Phages cocktail, Standard of care : Silver Sulfadiazine, P. Aeruginosa, Phages cocktail
- Where
- 5 sites in Belgium, France and 1 more
- Sponsor
- Phagenix
Cystic Fibrosis
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare…
- Trial name
- CT03 Core (NCT00885365)
- Testing
- tobramycin / Bramitob, tobramycin / TOBI
- Where
- 44 sites in Czechia, France and 6 more
- Volunteers
- 324 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pseudomonas Aeruginosa
Pathobiomes in Gut of Critically Ill Patients
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain…
- Trial name
- NCT06822465
- Testing
- P. aeruginosa using in vitro and in vivo assays
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Health Care Associated Infection, Hand Hygiene
Reducing Intraoperative Infection Transmission in the Pediatric Operating Room
Patients becoming infected during hospitalization occurs frequently and causes harm. It is important for healthcare facilities to take action to prevent these infections and their spread between patients.
- Trial name
- NCT03992209
- Testing
- Standard care, Protocolized care
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis, Lung Infection
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second…
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Trial name
- AIR-CF4 (NCT00712166)
- Testing
- AZLI 75 mg three times daily (TID)
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 160 people
- Sponsor
- Gilead Sciences
Surgical Site Infection, Staphylococcus Aureus Infection
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S.
- Conditions
- Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection, Bacterial Infections
- Trial name
- NCT06319235
- Testing
- IMP
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- MB PHARMA s.r.o.
Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
The use of inhaled medications for the treatment of pulmonary diseases allows for the delivery of a high concentration of a drug at the site of disease with reduced systemic absorption and risk of systemic adverse effects.
- Trial name
- TOBI (NCT02102152)
- Testing
- Tobramycin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Pseudomonas Aeruginosa Infection
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
A major factor in the respiratory health of Cystic Fibrosis (CF) participants is the prevalence of chronic Pseudomonas aeruginosa (Pa) infections.
- Trial name
- NCT01315678
- Testing
- Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer., Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
- Where
- 62 sites in Austria, Belgium and 16 more
- Volunteers
- 302 people
- Sponsor
- Insmed Incorporated
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no…
- Trial name
- NCT03395743
- Testing
- AB-PA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Multi-Drug Resistant Organism
Sentinel Cohort REACT
The purpose of this study is to better understand the efficacy and safety of microbiome therapies (MT) in patients with Multidrug Resistant Organism (MDRO) colonization who are admitted to Long Term Acute Care Hospitals (LTACH).
- Trial name
- NCT05780801
- Testing
- Allogeneic Microbiota in Glycerol (10%) (AMG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- NCT00499720
- Testing
- Aztreonam Lysine for Inhalation
- Where
- 65 sites in United States, Puerto Rico
- Sponsor
- Gilead Sciences
Pseudomonas Aeruginosa Meningitis
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
Meningitis is an infection where morbidity and mortality depend on the delay of the initial treatment for a good prognostic. The antibiotherapy rapidity allows to decrease the mortality.
- Trial name
- NCT00752882
- Testing
- ceftazidime
- Volunteers
- 24 people
- Sponsor
- University Hospital, Clermont-Ferrand
Cystic Fibrosis, Pseudomonas Aeruginosa
Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
The purpose of this study is to determine whether the nasal inhalation of Colistin is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.
- Trial name
- NCT01035853
- Testing
- Colistin
- Where
- 3 sites in Germany
- Volunteers
- 10 people
- Sponsor
- University of Jena